Addressing Gaps In The CGT Market Through Partnership

Mesenchymal stromal cell (MSC) therapies hold significant promise across regenerative medicine and immunomodulatory applications, yet variability in source material, donor characteristics, manufacturing processes, and preservation methods continues to challenge reproducibility and commercialization. This presentation explores how standardizing MSC development can help reduce risk from early research through translational and clinical workflows. It highlights the impact of donor-to-donor variability, the importance of defined potency and functionality, and the role of quality-focused manufacturing approaches in generating more consistent cell products. The collaboration between NextCell Pharma and FUJIFILM Biosciences demonstrates how combining standardized umbilical cord-derived MSC starting materials with optimized, xeno-free culture systems can support more reliable research outcomes and scalable manufacturing.

Gain insight into a practical framework that improves consistency and builds a stronger foundation for therapeutic development.